Copyright Markets Insider
Eisai (ESAIY) and Biogen (BIIB) announced that Health Canada has issued a Notice of Compliance with Conditions for humanized anti-soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease who are apolipoprotein E 4 non-carriers or heterozygotes and who have confirmed amyloid pathology. LEQEMBI is the first treatment for early AD that targets an underlying cause of the disease, to be authorized in Canada. Elevate Your Investing Strategy:
